email article
Bamlanivimab, the monoclonal antibody authorized to treat less-severe cases of COVID-19, reduced the risk of contracting symptomatic disease among nursing home residents and staff in the placebo-controlled BLAZE-2 trial, said manufacturer Eli Lilly on Thursday.
After 8 weeks of follow-up, incidence of symptomatic COVID-19 was significantly lower among all individuals receiving the drug compared with placebo (OR 0.43).
And a pre-specified group of nursing home residents had even lower odds of symptomatic disease than those in the control group (OR 0.20), the company said.
These results of the phase III BLAZE-2 trial were announced via press release. The trial was conducted in partnership with the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, and the COVID-19 Prevention Network. Lilly promised to submit the data for peer-reviewed publication and presentation at a future medical meeting.
A study of nursing home residents found the monoclonal antibody treatment bamlanivimab cut the risk of COVID-19 by up to 80%, maker Eli Lilly announced.